Summary
Both the PILLAR [TMC435-C205; NCT00882908] and ASPIRE [TMC435-C206; NCT00980330] trials demonstrated that TMC435 (an oral inhibitor of the hepatitis C virus NS3/4A protease) administered once-daily with pegylated interferon alpha-2a (PegIFNa-2a) and ribavirin (RBV) is safe, has potent antiviral activity, and shortens total treatment by 24 weeks compared with PegIFNa-2a/RBV alone.
- Viral Infections
- Infectious Disease Trials
- © 2011 MD Conference Express
Tools
Table of contents
Cited By...
- No citing articles found.